ABCL Nasdaq Pharmaceutical Preparations Financials FY2019βFY2025
AbCellera Biologics Inc. had $75.1M of revenue in fiscal 2025, up 160.6% on the year before. Over five years, revenue changed β20.3% a year on average.
Last close Β· Oct 23, 2026
$11.82
4.0%Hi! I read AbCellera Biologics Inc.βs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Are sales growing?
+160.6%
Yes. Sales grew 160.6% last year.
Does it make a profit?
β194.9%
No. It lost money last year.
Does profit turn into cash?
β231.7%
No. It spent more cash than it brought in.
How healthy are the accounts?
4 / 7
Mixed. It passes 4 of 7 health tests.
How is the share priced?
β
No P/E: it made no profit over the last four quarters.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
In plain words: Every quarter, companies publish how much they sold and earned. These are the days AbCellera Biologics Inc. did it, and the next one. Share prices often move a lot on those days.
Next results
November 9, 2026
Monday Β· in 15 days
| Date | Results for | Time | Source |
|---|---|---|---|
| Aug 5, 2026 | Q2 '26 | After the market closes | 8-K β |
| May 11, 2026 | Q1 '26 | After the market closes | 8-K β |
| Feb 24, 2026 | Q4 '25 | After the market closes | 8-K β |
| Nov 6, 2025 | Q3 '25 | After the market closes | 8-K β |
| Aug 7, 2025 | Q2 '25 | After the market closes | 8-K β |
| May 8, 2025 | Q1 '25 | After the market closes | 8-K β |
| Feb 27, 2025 | Q4 '24 | After the market closes | 8-K β |
| Nov 4, 2024 | Q3 '24 | After the market closes | 8-K β |
From SEC filings: the results press release (8-K) or, without one, the quarterly or annual report.
KIRA Β· AbCellera Biologics Inc. had $75.1M of revenue in fiscal 2025, up 160.6% on the year before. Over five years, revenue changed β20.3% a year on average. Its operating margin was β289.0%, up 802.7Β pts: of every 100 in sales, about β289 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
KIRA Β· AbCellera Biologics Inc. lost $146M in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
How much cash comes in, and where does it go?
KIRA Β· Free cash flow was β$174M in fiscal 2025, β231.7% of revenue.
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
KIRA Β· No open-market insider trades in the last 12 months.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Can it carry its debts, and how well does it use its money?
Cash, debt and the ratios that show how comfortably AbCellera Biologics Inc. can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $476M | $387M | $133M | $156M | $129M |
| Current ratio | 7.7x | 8.7x | 7.3x | 9.8x | 11.3x |
| Quick ratio | 7.7x | 8.7x | 7.3x | 9.8x | 11.2x |
| Total assets | $1.3B | $1.5B | $1.5B | $1.4B | $1.4B |
| Total liabilities | $293M | $308M | $336M | $304M | $390M |
| Shareholders' equity | $1.0B | $1.2B | $1.2B | $1.1B | $967M |
| Net debt (β = net cash) | β | β | β | β | β |
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
KIRA Β· AbCellera Biologics Inc. passes 4 of 7 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β |
| F-score | β / 3 | β / 4 | 4 / 7 | 6 / 7 | 2 / 7 | 2 / 7 | 4 / 7 |
| Accruals ratio | β | 9.6% | β7.8% | β8.3% | β6.8% | β3.8% | β1.1% |
| Altman Z'' | β | 11.03 | 9.41 | 9.92 | 6.46 | 5.62 | 4.67 |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | $11.6M | $233M | $375M | $485M | $38.0M | $28.8M | $75.1M |
| Research and development | $10.1M | $29.4M | $62.1M | $108M | $176M | $167M | $187M |
| Operating income | β$4.1M | $156M | $204M | $217M | β$237M | β$315M | β$217M |
| Pretax income | β$2.2M | $158M | $219M | $239M | β$174M | β$200M | β$178M |
| Income tax | β | $38.9M | $65.7M | $80.6M | β$27.6M | β$37.5M | β$31.2M |
| Net income | β$2.2M | $119M | $153M | $159M | β$146M | β$163M | β$146M |
| Net income to common | β$2.2M | $85.1M | $153M | $159M | β$146M | β$163M | β$146M |
| Diluted EPS | β$0.01 | $0.45 | $0.48 | $0.50 | β$0.51 | β$0.55 | β$0.49 |
| Diluted shares | 0.15B | 0.26B | 0.32B | 0.31B | 0.29B | 0.29B | 0.30B |
| Cash flow | |||||||
| Cash from operations | $2.7M | $22.7M | $245M | $277M | β$43.9M | β$109M | β$131M |
| Capital expenditure | $4.0M | $9.7M | $58.5M | $70.7M | $76.9M | $78.4M | $42.8M |
| Free cash flow | β$1.3M | $13.0M | $186M | $207M | β$121M | β$187M | β$174M |
| Depreciation and amortization | $1.6M | $4.8M | $14.5M | $27.8M | $24.4M | $12.5M | $18.4M |
| Stock-based compensation | $0.9M | $8.4M | $30.6M | $49.5M | $64.2M | $67.6M | $55.8M |
| Acquisitions | β | $87.6M | $11.5M | $0.0M | $0.0M | β | β |
| Balance sheet | |||||||
| Cash and short-term investments | β | $594M | $476M | $387M | $133M | $156M | $129M |
| Total debt | β | $0.2M | β | β | β | β | β |
| Current assets | β | $813M | $930M | $1.0B | $872M | $751M | $728M |
| Current liabilities | β | $103M | $121M | $118M | $119M | $76.6M | $64.3M |
| Inventory | β | β | β | β | β | $0.0M | $6.3M |
| Property and equipment, net | β | $17.9M | $112M | $217M | β | β | β |
| Goodwill | β | $31.5M | $47.8M | $47.8M | $47.8M | $47.8M | $47.8M |
| Intangible assets | $0.0M | $115M | $148M | $132M | $120M | $42.1M | $38.4M |
| Total assets | β | $1.0B | $1.3B | $1.5B | $1.5B | $1.4B | $1.4B |
| Total liabilities | β | $175M | $293M | $308M | $336M | $304M | $390M |
| Shareholders' equity | $10.3M | $831M | $1.0B | $1.2B | $1.2B | $1.1B | $967M |
| Margins | |||||||
| Operating margin | β35.5% | 66.9% | 54.5% | 44.6% | β623.8% | β1,091.7% | β289.0% |
| EBITDA margin | β21.6% | 69.0% | 58.3% | 50.3% | β559.7% | β1,048.2% | β264.4% |
| Net margin | β19.0% | 51.0% | 40.9% | 32.7% | β385.0% | β564.8% | β194.9% |
| FCF margin | β11.2% | 5.6% | 49.6% | 42.6% | β317.7% | β648.4% | β231.7% |
| Returns | |||||||
| Return on capital | β | 49.7% | β | β | β | β | β |
| Return on capital employed | β | 17.3% | 17.1% | 15.2% | β17.3% | β24.5% | β16.8% |
| Return on equity | β21.6% | 28.3% | 16.5% | 14.0% | β12.3% | β14.7% | β14.5% |
| Return on assets | β | 11.8% | 13.2% | 11.1% | β9.7% | β11.4% | β10.8% |
| Return on tangible equity | β21.6% | 12.4% | 18.5% | 15.0% | β14.9% | β16.9% | β16.6% |
| Growth | |||||||
| Revenue growth | β | 1,907.9% | 60.9% | 29.4% | β92.2% | β24.2% | 160.6% |
| Net income growth | β | β | 29.1% | 3.3% | β192.4% | β | β |
| EPS growth | β | β | 6.7% | 4.2% | β202.0% | β | β |
| FCF growth | β | β | 1,329.9% | 11.1% | β158.5% | β | β |
| Share count change | β | 73.9% | 21.0% | β1.1% | β8.2% | 1.8% | 1.5% |
| Financial health | |||||||
| Net debt / EBITDA | β | β3.7x | β | β | β | β | β |
| Debt / equity | β | 0.0x | β | β | β | β | β |
| Current ratio | β | 7.9x | 7.7x | 8.7x | 7.3x | 9.8x | 11.3x |
| Quick ratio | β | 7.9x | 7.7x | 8.7x | 7.3x | 9.8x | 11.2x |
| Capital allocation | |||||||
| Capex / revenue | 34.4% | 4.1% | 15.6% | 14.6% | 202.4% | 271.9% | 56.9% |
| Stock comp / revenue | 7.7% | 3.6% | 8.2% | 10.2% | 168.8% | 234.4% | 74.3% |
| Quality scores | |||||||
| Piotroski F-score | β | β | 4.0 | 6.0 | 2.0 | 2.0 | 4.0 |
| Altman Z'' | β | 11.0 | 9.4 | 9.9 | 6.5 | 5.6 | 4.7 |
| Accruals ratio | β | 9.6% | β7.8% | β8.3% | β6.8% | β3.8% | β1.1% |
Source: SEC EDGAR XBRL filings (CIK 0001703057). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.
